Fanconi anemia and the development of leukemia

Blanche P. Alter

Research output: Contribution to journalArticle

Abstract

Fanconi anemia (FA) is a rare autosomal recessive cancer-prone inherited bone marrow failure syndrome, due to mutations in 16 genes, whose protein products collaborate in a DNA repair pathway. The major complications are aplastic anemia, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and specific solid tumors. A severe subset, due to mutations in FANCD1/BRCA2, has a cumulative incidence of cancer of 97% by age 7 years; the cancers are AML, brain tumors, and Wilms tumor; several patients have multiple events. Patients with the other genotypes (FANCA through FANCQ) have cumulative risks of more than 50% of marrow failure, 20% of AML, and 30% of solid tumors (usually head and neck or gynecologic squamous cell carcinoma), by age 40, and they too are at risk of multiple adverse events. Hematopoietic stem cell transplant may cure AML and MDS, and preemptive transplant may be appropriate, but its use is a complicated decision.

Original languageEnglish (US)
Pages (from-to)214-221
Number of pages8
JournalBest Practice and Research: Clinical Haematology
Volume27
Issue number3-4
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Fanconi Anemia
Tumors
Leukemia
Acute Myeloid Leukemia
Transplants
Myelodysplastic Syndromes
Neoplasms
Stem cells
Mutation
Wilms Tumor
Aplastic Anemia
Brain
Hematopoietic Stem Cells
Bone
Repair
Brain Neoplasms
DNA Repair
Squamous Cell Carcinoma
Neck
Bone Marrow

Keywords

  • bone marrow failure
  • Fanconi anemia
  • leukemia
  • myelodysplastic syndrome
  • stem cell transplant

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Cite this

Fanconi anemia and the development of leukemia. / Alter, Blanche P.

In: Best Practice and Research: Clinical Haematology, Vol. 27, No. 3-4, 01.09.2014, p. 214-221.

Research output: Contribution to journalArticle

Alter, Blanche P. / Fanconi anemia and the development of leukemia. In: Best Practice and Research: Clinical Haematology. 2014 ; Vol. 27, No. 3-4. pp. 214-221.
@article{bade11244da64603be35839f2ee6cdc5,
title = "Fanconi anemia and the development of leukemia",
abstract = "Fanconi anemia (FA) is a rare autosomal recessive cancer-prone inherited bone marrow failure syndrome, due to mutations in 16 genes, whose protein products collaborate in a DNA repair pathway. The major complications are aplastic anemia, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and specific solid tumors. A severe subset, due to mutations in FANCD1/BRCA2, has a cumulative incidence of cancer of 97{\%} by age 7 years; the cancers are AML, brain tumors, and Wilms tumor; several patients have multiple events. Patients with the other genotypes (FANCA through FANCQ) have cumulative risks of more than 50{\%} of marrow failure, 20{\%} of AML, and 30{\%} of solid tumors (usually head and neck or gynecologic squamous cell carcinoma), by age 40, and they too are at risk of multiple adverse events. Hematopoietic stem cell transplant may cure AML and MDS, and preemptive transplant may be appropriate, but its use is a complicated decision.",
keywords = "bone marrow failure, Fanconi anemia, leukemia, myelodysplastic syndrome, stem cell transplant",
author = "Alter, {Blanche P.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1016/j.beha.2014.10.002",
language = "English (US)",
volume = "27",
pages = "214--221",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "3-4",

}

TY - JOUR

T1 - Fanconi anemia and the development of leukemia

AU - Alter, Blanche P.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Fanconi anemia (FA) is a rare autosomal recessive cancer-prone inherited bone marrow failure syndrome, due to mutations in 16 genes, whose protein products collaborate in a DNA repair pathway. The major complications are aplastic anemia, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and specific solid tumors. A severe subset, due to mutations in FANCD1/BRCA2, has a cumulative incidence of cancer of 97% by age 7 years; the cancers are AML, brain tumors, and Wilms tumor; several patients have multiple events. Patients with the other genotypes (FANCA through FANCQ) have cumulative risks of more than 50% of marrow failure, 20% of AML, and 30% of solid tumors (usually head and neck or gynecologic squamous cell carcinoma), by age 40, and they too are at risk of multiple adverse events. Hematopoietic stem cell transplant may cure AML and MDS, and preemptive transplant may be appropriate, but its use is a complicated decision.

AB - Fanconi anemia (FA) is a rare autosomal recessive cancer-prone inherited bone marrow failure syndrome, due to mutations in 16 genes, whose protein products collaborate in a DNA repair pathway. The major complications are aplastic anemia, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and specific solid tumors. A severe subset, due to mutations in FANCD1/BRCA2, has a cumulative incidence of cancer of 97% by age 7 years; the cancers are AML, brain tumors, and Wilms tumor; several patients have multiple events. Patients with the other genotypes (FANCA through FANCQ) have cumulative risks of more than 50% of marrow failure, 20% of AML, and 30% of solid tumors (usually head and neck or gynecologic squamous cell carcinoma), by age 40, and they too are at risk of multiple adverse events. Hematopoietic stem cell transplant may cure AML and MDS, and preemptive transplant may be appropriate, but its use is a complicated decision.

KW - bone marrow failure

KW - Fanconi anemia

KW - leukemia

KW - myelodysplastic syndrome

KW - stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=84923922333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923922333&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2014.10.002

DO - 10.1016/j.beha.2014.10.002

M3 - Article

VL - 27

SP - 214

EP - 221

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 3-4

ER -